An interventional study of Structured video telemedicine visit in Systemic Lupus Erythematosus, sponsored by Baylor College of Medicine. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-25.
Sponsored by Baylor College of Medicine · Not applicable, Interventional, and Health services research
This study seeks to determine the feasibility, effectiveness and safety of a structured video telemedicine program for the treatment of patients with systemic lupus erythematous in a under-resourced clinic. Patients with SLE who are interested in participating, with low disease activity, will be randomized to video or in person clinic visit for their next clinical visit. They will cross over to the other group for their follow up appointment in 3 months.
This study seeks to determine the feasibility, effectiveness and safety of a structured video telemedicine program for the treatment of patients with systemic lupus erythematous in a under-resourced clinic. Patients with SLE who are interested in participating, with low disease activity, will be randomized to video or in person clinic visit for their next clinical visit. They will cross over to the other group for their follow up appointment in 3 months. Data obtained include patient's SLE disease activity, laboratory results, patient satisfaction and surveys of telemedicine.
Exclusion Criteria:
- Patients with moderate to high disease activity as defined by a SLEDAI score of more than 5.
Patients randomized to group 1 will have a telemedicine visit in 3 months followed by an in person visit in 6 months
Behavioral: Structured video telemedicine visit
Patients randomized to group 1 will have an in person visit in 3 months followed by a telemedicine visit in 6 months
Behavioral: Structured video telemedicine visit
Patients will be randomized to a 3 month follow up visit of video or in person, then cross over at 6 months to the other arm
Telehealth Usability Questionaire (TUQ), Total Overall Score
Telehealth Usability Questionaire (TUQ), Total Overall Score is derived by adding up the liker scale response (1 = Strongly disagree, 7 = Stronly agree) for each of the 21 questions and dividing by 21 to get a total overall score from 1-7 (1 = Strongly disagree, 7 = Stronly agree)
Time frame: 3 and 6 months
No show rate
The percent of visits where the patient did not show for the appointment
Time frame: 3 and 6 months
laboratory utilization
The number of visits where the patient successfully obtained the required order labs for the monitoring of disease activity
Time frame: 3 and 6 months
Disease activity as measured by Safety of Estrogens in Lupus Erythematosus National Assessment - Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI)
Lupus disease activity will be measured by the SELENA-SLEDAI disease activity assessment tool Scale is 0 to 105 0 = no activity of disease, 105 = maximal activity of disease
Time frame: 3 and 6 months
Physician global assessment
The assessment of the patient's lupus disease activity based on liker scale as answered by the physician Scale 0-10 O = no disease activity as assesed by physician, 10 = maximal disease activity assessed by physician
Time frame: 3 and 6 months
Patient global assessment
The assessment of the patient's lupus disease activity based on likert scale as answered by the patient Scale 0-10 O = no disease activity as assesed by patient, 10 = maximal disease activity assessed by patient
Time frame: 3 and 6 months
Lupus flare rate
Assessment of flare of lupus activity based on Safety of Estrogens in Lupus Erythematosus National Assessment - Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI), comparing prior baseline assessment to the 3 and 6 month visit assessment
Time frame: 3 and 6 months
Acute care utilization
Number of patients who required a visit to the urgent care of emergency room prior to the visit
Time frame: 3 and 6 months
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Lupus Erythematosus, Systemic→
Baylor College of Medicine